
The FDA has made the decision to add a warning to the fact sheet for Johnson & Johnson’s COVID-19 vaccine, …

Johnson & Johnson’s interleukin-23 (IL-23) Tremfya (guselkumab) has shown positive results in Phase IIIb trials, in post-tumour necrosis factor (TNF) …

The Johnson & Johnson COVID-19 vaccine will continue its rollout in Europe, following a review from the EMA.

The EMA is reviewing reports of rare blood clots in four people in the US who received Johnson & Johnson’s …

Johnson & Johnson has said that it is injecting around $1 billion of funding into its research efforts to develop …

Johnson & Johnson has kicked off a second global Phase 3 trial to assess the safety and efficacy of its …

Johnson & Johnson has suffered a legal defeat in its ongoing dispute with consumers over damages relating to use of …

Johnson & Johnson will pay another $1 billion to settle lawsuits alleging it fuelled the opioid crisis in the US. …

Johnson & Johnson has announced its decision to slam the brakes on the development programme for its COVID-19 vaccine following …

Johnson & Johnson’s vaccine candidate for COVID-19 has shown efficacy in a small group of Syrian golden hamsters.

The UK Government has signed a new deal with Johnson & Johnson and Novavax to secure 90 million orders of …

The US will pay Johnson and Johnson more than $1 billion to create 100 million doses of COVID-19 vaccine. The …

In the latest chapter in Johnson & Johnson’s talc-related woes, the company is being pressured by group of over 170 …

As many pharma firms move to secure upscaled manufacturing capacity for their potential COVID-19 vaccines, Johnson & Johnson’s Janssen has …

Johnson & Johnson have announced that it will cut the price of its tuberculosis drug Bedaquiline, sold under the brand …